The IPO Buzz: After Presidents Day, A Light Menu for A Short Holiday Week

The IPO menu for this four-day work week is more like a dim sum or a dietitian’s snack tray instead of a meal. The U.S. stock market was closed on Monday, Feb. 17, 2025, for Presidents Day, a federal holiday. Only three small IPOs are on the IPO Calendar for the week of Feb. 18, 2025, when bankers expect to raise about $33.6 million – if all of those deals are priced at the mid-point of their respective ranges. That’s a far cry from last week’s lineup of 10 deals that raised $2.65 billion. Health care is the sector in focus this week: Anbio Biotechnology (NNNN Proposed), a Frankfurt, Germany-based company focused on early screening and diagnosis of cancer, cardiovascular and renal disorders as well as diabetes, is expected to price its $8.8 million IPO tonight – Tuesday, Feb. 18. AC Sunshine Securities is the sole book-runner. This is a NASDAQ listing. Wellgistics Health (WGRX Proposed), a Tampa, Florida-based healthcare holding company, is set to price its $4.5 million IPO on Wednesday night, Feb. 19, 2025. Craft Capital and D. Boral Capital (formerly EF Hutton) are the joint book-runners. This is a NASDAQ listing. Wellgistics Health’s operating subsidiaries include a pharmacy, a wholesale business that includes the distribution and fulfillment of certain pharmaceutical medications to a network of independent pharmacies, and a technology division with a novel platform for hub and clinical services. Apimeds Pharmaceuticals US (APUS Proposed), a Hopewell, New Jersey-based clinical biopharmaceutical company, is expected to price its $20.3 million IPO on Thursday night, Feb. 20, 2025. D. Boral Capital is the sole book-runner. This is an NYSE – American Exchange listing. Apimeds Pharmaceuticals US is developing Apitox, an intradermal injection derived from bee venom, to treat inflammation and pain associated with osteoarthritis of the knee. The company is planning a second Phase 3 trial of Apitox, according to the prospectus. Its previous Phase 3 trial completed in 2018 did not meet the FDA’s standards for approval, the prospectus said.   A Tale of Two IPOs Last week, the two high-profile IPOs provided a study in contrast: *SailPoint (SAIL), an identity software maker, raised $1.38 billion by upsizing its IPO by 20 percent at pricing to 60.0 million shares and pricing the IPO at $23.00, the top of its recently increased range. SailPoint ended its first day of trading – Thursday, Feb. 13, 2025 – at $22.00 – $1.00 below its IPO price – and closed out the week by ending Friday’s session on Feb. 14 at $24.55 on NASDAQ. *Karman Holdings (KRMN), a space and defense contractor, raised $506.0 million by upsizing its IPO by 9.3 percent to 23.0 million shares and pricing the IPO at $22.00 – $2.00 above the top of its range. Karman Holdings ended its first day of trading – Thursday, Feb. 13, 2025 – at $30.05 – up $8.05 from its IPO price – and closed out the week by ending Friday’s session on Feb. 14 at $32.00 – up $10.00 from its IPO price – on the New York Stock Exchange. Stay tuned. (For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com  website.) Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board. To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message. Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions. Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the  shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.